ADMIRE-HF Extensive (X) Trial: Predicting Cardiac and All-Cause Mortality Using 123I-mIBG Myocardial Scintigraphy in Heart Failure Patients

PRNewswire -- Today, researchers presented new data showing molecular imaging agent 123I-mIBG can help cardiologists define risk in heart failure patients. As an extension of the ADMIRE-HF trial, the ADMIRE-HFX study assessed 123I-mIBG as a risk stratifier for arrhythmic events and cardiac death in subjects with heart failure.